Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.55 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.55 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 8/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25210861 | 0.91 | EGFR (0.69) | EGFRERBB2ERBB3DUS2KDR | |
| SCHEMBL25214496 | 0.90 | EGFR (0.68) | EGFRERBB2ERBB3DUS2KDR | |
| SCHEMBL25372048 | 0.89 | EGFR (0.68) | EGFRERBB2ERBB3DUS2KDR | |
| SCHEMBL30429607 | 0.89 | EGFR (0.48) | EGFRERBB2ERBB3DUS2KDR | |
| SCHEMBL25267390 | 0.89 | EGFR (0.48) | EGFRERBB2ERBB3DUS2KDR | |
| SCHEMBL25258592 | 0.88 | EGFR (0.53) | EGFRERBB2ERBB3DUS2KDR | |
| SCHEMBL25663462 | 0.85 | EGFR (0.45) | EGFRKDR | |
| SCHEMBL25212876 | 0.84 | EGFR (0.64) | EGFRERBB2ERBB3KDR | |
| SCHEMBL25212428 | 0.84 | EGFR (0.72) | EGFRERBB2ERBB3KDR | |
| SCHEMBL25369245 | 0.84 | EGFR (0.68) | EGFRERBB2ERBB3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-4194443-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| EP-4194443-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | EGFR, WEE1, WEE2 | EGFR 1/4885ERBB2 5/4885ERBB3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.